Promega Research Shows Potential of Selective Degrader Against Pediatric Cancer Cell Lines
Promega research published today in Nature Communications demonstrates a new potential approach for managing multiple myeloma and other hematological cancers.
- Promega research published today in Nature Communications demonstrates a new potential approach for managing multiple myeloma and other hematological cancers.
- The molecule, called SJ3149, demonstrates potent anti-proliferative activity in a variety of human cancer cell lines through selective degradation of the cancer-causing protein CK1α.
- They report that SJ3149 potently and selectively degrades CK1α and limits the proliferation of multiple cancer cell lines spanning a wide range of disease subtypes.
- Their results strongly support future research on applying selective CK1α degraders to many different cancer types.